For­get RNA drugs. Ac­cent gets $40M to de­vel­op small mol­e­cules that mod­i­fy RNA in­stead

A Cam­bridge start­up is step­ping out to­day with some rev­e­la­tions on how pro­teins tweak RNA — and sub­se­quent­ly how a cell’s char­ac­ter and func­tion is de­ter­mined. The com­pa­ny, called Ac­cent Ther­a­peu­tics, scored $40 mil­lion in launch mon­ey to see if their new tech can de­liv­er pre­ci­sion meds in can­cer.

The im­pe­tus for the com­pa­ny’s launch is a new un­der­stand­ing of RNA-mod­i­fy­ing pro­teins, and how they might link to dis­ease. Ac­cent’s new find­ings in the field just got pub­lished to­day in Na­ture Re­views Drug Dis­cov­ery.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER